Intravitreal triamcinolone versus bevacizumab for treatment of refractory diabetic macular oedema (IBEME study)

Página do item simplificado
dc.contributor.authorPaccola, L.
dc.contributor.authorCosta, R. A.
dc.contributor.authorFolgosa, M. S.
dc.contributor.authorBarbosa, J. C. [UNESP]
dc.contributor.authorScott, I. U.
dc.contributor.authorJorge, R.
dc.contributor.institutionUniversidade de São Paulo (USP)
dc.contributor.institutionHosp Olhos Araraquara
dc.contributor.institutionUniversidade Estadual Paulista (Unesp)
dc.contributor.institutionPenn State Coll Med
dc.date.accessioned2014-05-20T13:13:41Z
dc.date.available2014-05-20T13:13:41Z
dc.date.issued2008-01-01
dc.description.abstractBackground/aims: The aim of this study was to compare the morphological and visual acuity outcomes associated with a single intravitreal injection of triamcinolone acetonide versus bevacizumab for the treatment of refractory diffuse diabetic macular oedema.Methods: Twenty-eight patients were randomly assigned to receive a single intravitreal injection of either 4 mg/0.1 ml triamcinolone acetonide or 1.5 mg/0.06 ml bevacizumab. Comprehensive ophthalmic evaluation was performed at baseline and at weeks 1, 4, 8 (+/- 1), 12 (+/- 2) and 24 (+/- 2) after treatment. Main outcome measures included central macular thickness measured with optical coherence tomography (OCT) and best corrected Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity.Results: Twenty-six patients (26 eyes) completed all study visits (two patients missed two consecutive study visits). Central macular thickness was significantly reduced in the intravitreal triamcinolone group compared with the bevacizumab group at weeks 4, 8, 12 and 24 (p<0.05). Logarithm of the minimum angle of resolution (LogMAR) best-corrected visual acuity was significantly higher at weeks 8 (0.69; similar to 20/100(+1)) and 12 (0.74; 20/100(-2)) in the intravitreal triamcinolone group compared with the bevacizumab group (weeks 8 (0.83; similar to 20/125(-1)) and 12 (0.86; 20/ 160(+2))) (p<0.05). Significant change from baseline in mean intraocular pressure (mmHg) was seen at week 4 (+2.25) only in the intravitreal triamcinolone group (p<0.0001). No patient had observed cataract progression during the study.Conclusions: One single intravitreal injection of triamcinolone may offer certain advantages over bevacizumab in the short-term management of refractory diabetic macular oedema, specifically with regard to changes in central macular thickness. The actual clinical relevance of our preliminary findings, however, remains to be determined in future larger studies.en
dc.description.affiliationUniv São Paulo, Dept Ophthalmol, Ribeirao Preto, SP, Brazil
dc.description.affiliationHosp Olhos Araraquara, Macular Imaging & Treatment Div, UDAT, Araraquara, SP, Brazil
dc.description.affiliationSão Paulo State Univ, Exact Sci Dept, Jaboticabal, SP, Brazil
dc.description.affiliationPenn State Coll Med, Dept Ophthalmol & Publ Hlth Sci, Hershey, PA USA
dc.description.affiliationUnespSão Paulo State Univ, Exact Sci Dept, Jaboticabal, SP, Brazil
dc.format.extent76-80
dc.identifierhttp://dx.doi.org/10.1136/bjo.2007.129122
dc.identifier.citationBritish Journal of Ophthalmology. London: B M J Publishing Group, v. 92, n. 1, p. 76-80, 2008.
dc.identifier.doi10.1136/bjo.2007.129122
dc.identifier.issn0007-1161
dc.identifier.urihttp://hdl.handle.net/11449/1396
dc.identifier.wosWOS:000252054700018
dc.language.isoeng
dc.publisherB M J Publishing Group
dc.relation.ispartofBritish Journal of Ophthalmology
dc.relation.ispartofjcr3.384
dc.relation.ispartofsjr2,173
dc.rights.accessRightsAcesso restrito
dc.sourceWeb of Science
dc.titleIntravitreal triamcinolone versus bevacizumab for treatment of refractory diabetic macular oedema (IBEME study)en
dc.typeArtigo
dcterms.licensehttp://www.bmj.com/about-bmj/resources-authors
dcterms.rightsHolderB M J Publishing Group
unesp.author.orcid0000-0002-0800-2233[2]
unesp.author.orcid0000-0002-2652-0720[6]
unesp.campusUniversidade Estadual Paulista (Unesp), Faculdade de Ciências Agrárias e Veterinárias, Jaboticabalpt

Arquivos

Licença do Pacote
Agora exibindo 1 - 2 de 2
Nenhuma Miniatura disponível
Nome:
license.txt
Tamanho:
1.71 KB
Formato:
Item-specific license agreed upon to submission
Descrição:
Nenhuma Miniatura disponível
Nome:
license.txt
Tamanho:
1.71 KB
Formato:
Item-specific license agreed upon to submission
Descrição:

Coleções

Artigos - Ciências Exatas - FCAV